PharmAbcine, Samsung Biologics expand partnership

By The Science Advisory Board staff writers

September 21, 2020 -- PharmAbcine and Samsung Biologics have entered into a new strategic partnership for the development and manufacturing of PMC-403, a next-generation antibody therapeutic candidate to treat neovascular disorders.

Samsung will provide contract development organization services including cell line development, process development, current good manufacturing practice clinical manufacturing, and investigational new drug filing support.

PMC-403 is a novel agonistic antibody that binds to the human Tie2 receptor. PharmAbcine is developing the therapy to treat nonocular and ocular pathological vessel-related diseases. The company expects PMC-403 to enter a global ophthalmological clinical trial in 2022.

This is PharmAbcine's first significant undertaking of its angiogenesis assets outside of oncology applications.

Samsung Biologics adds new manufacturing plant
Samsung Biologics announced that it plans to break ground on a fourth plant in South Korea this year as part of a strategy to scale up development and...
Thermo Fisher to develop, manufacture next-gen immunotherapy
Thermo Fisher Scientific has formed a strategic partnership with PharmAbcine for the development and manufacturing of PMC-309, a next-generation immune...
Samsung Biologics, Vir partner on SARS-CoV-2 program
Samsung Biologics announced it will manufacture Vir Biotechnology's SARS-CoV-2 monoclonal antibody program for a potential COVID-19 treatment.

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
Festival of Genomics & Biodata
January 28-29, 2021
London, Greater London United Kingdom
Lab of the Future USA
May 11-12, 2021
Boston, Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter